Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027

HCA Healthcare received a bullish reaffirmation from Bernstein with projected EBITDA growth of 2.8% (2026) and 4.6% (2027), suggesting analyst confidence in operational execution despite macro headwinds. The stock's forward P/E of 12.27 positions it as one of the lowest-valued names in the S&P 500, indicating potential valuation upside of 38.4%—a meaningful discount relative to historical health care multiples.

The cautious macro backdrop cited by analysts reflects broader healthcare sector pressures: labor cost inflation, reimbursement constraints, and operational complexity. However, HCA's continued investment in workforce development signals management prioritization of long-term competitive positioning over near-term margin expansion. This contrasts with sector peers pursuing aggressive cost-cutting, potentially positioning HCA favorably during eventual economic stabilization.

The low forward P/E multiple combined with positive EBITDA trajectory suggests the market has priced in conservative outcomes. If Bernstein's projections materialize, upside realization depends on investor sentiment shift toward healthcare cyclicals and operational leverage from revenue growth exceeding cost inflation.

Sector implication: HCA's valuation and growth profile represent a selective bright spot within Health Care, which faces structural headwinds. The analyst stance reflects confidence in hospital operator resilience, though sector rotation risk remains if macro conditions deteriorate further or if labor-cost pressures accelerate.